SCHEMBL409050

SCHEMBL409050

C[C@H](Nc1cccc2ccccc12)C(=O)O.C[C@H](Nc1cccc2ccccc12)C(=O)O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 2/20 0.54
CA14 Q9ULX7 2/20 0.54
CA2 P00918 1/20 0.54
MMP2 P08253 1/20 0.54
MMP9 P14780 1/20 0.54
MMP8 P22894 1/20 0.54
MMP14 P50281 1/20 0.54
KDM4E B2RXH2 5/20 0.51
CYP3A4 P08684 3/20 0.51
CYP1A2 P05177 2/20 0.51
CYP2C9 P11712 2/20 0.51
CYP2C19 P33261 2/20 0.51
GAA P10253 1/20 0.51
NPC1 O15118 1/20 0.51
CYP2D6 P10635 1/20 0.51
RAB9A P51151 1/20 0.51
MEN1 O00255 5/20 0.51
KMT2A Q03164 5/20 0.51
MAPT P10636 4/20 0.51
TNNI3 P19429 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL298855 1.00 CA12 (0.54) CA12CA14CA2MMP2MMP9
SCHEMBL29367675 1.00 CA12 (0.54) CA12CA14CA2MMP2MMP9
SCHEMBL42287 1.00 CA12 (0.54) CA12CA14CA2MMP2MMP9
SCHEMBL29478385 1.00 CA12 (0.54) CA12CA14CA2MMP2MMP9
SCHEMBL42286 1.00 CA12 (0.54) CA12CA14CA2MMP2MMP9
Hydrochloric Acid SCHEMBL21433626 0.98 CA12 (0.53) CA12CA14CA2MMP2MMP9
Ammonia Solution, Strong SCHEMBL466944 0.98 CA12 (0.53) CA12CA14CA2MMP2MMP9
Hydrochloric Acid SCHEMBL21433625 0.98 CA12 (0.53) CA12CA14CA2MMP2MMP9
Ammonia Solution, Strong SCHEMBL466943 0.98 CA12 (0.53) CA12CA14CA2MMP2MMP9
Hydrochloric Acid SCHEMBL6420699 0.98 CA12 (0.53) CA12CA14CA2MMP2MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210030918-A1 COATING OF FIBERS WITH DIPEPTIDE NANOSTRUCTURES USING ULTRASONIC CAVITATION RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2021-02-04 US claimed
US-20170209845-A1 FORMATION OF ORGANIC NANOSTRUCTURE ARRAY RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2017-07-27 US claimed
EP-2089418-B1 FORMATION OF ORGANIC NANOSTRUCTURE ARRAY UNIV RAMOT (IL) 2016-11-09 EP claimed
EP-2961433-A1 PEPTIDE-BASED HYDROGEL PARTICLES AND USES THEREOF Ramot at Tel-Aviv University Ltd. (IL) 2016-01-06 EP claimed
EP-1781310-B1 ARTICLES OF PEPTIDE NANOSTRUCTURES AND METHOD OF FORMING THE SAME UNIV RAMOT (IL) 2015-10-14 EP claimed
US-9074095-B2 Malleable hydrogel hybrids made of self-assembled peptides and biocompatible polymers and uses thereof TECHNOLOGY INNOVATION MOMENTUM FUND (ISRAEL) LIMITED PARTNERSHIP (IL) 2015-07-07 US claimed
US-8927689-B2 Peptide nanostructures and methods of generating and using the same RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2015-01-06 US claimed
WO-2014132262-A1 PEPTIDE-BASED HYDROGEL PARTICLES AND USES THEREOF RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2014-09-04 WO claimed
US-8796023-B2 Peptide nanostructures containing end-capping modified peptides and methods of generating and using the same RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2014-08-05 US claimed
US-20140027655-A1 PEPTIDE NANOSTRUCTURES AND METHODS OF GENERATING AND USING THE SAME RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2014-01-30 US claimed
US-7504383-B2 Peptide nanostructures encapsulating a foreign material and method of manufacturing same RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) 2009-03-17 US claimed
US-7491699-B2 Peptide nanostructures and methods of generating and using the same RAMOT AT TEL AVIV UNIVERSITY LTD. 2009-02-17 US claimed
EP-1973928-A2 SELF-ASSEMBLED FMOC-FF HYDROGELS Ramot at Tel-Aviv University Ltd. (IL) 2008-10-01 EP claimed
US-20080009434-A1 at least one aromatic amino acid (phenylalanine); hollow and fibrillar peptide; macroscopic and microscopic articles; self-assembled; 9-fluorenylmethyloxycarbonyl (Fmoc) and benzyloxycarbonyl (Cbz); slow release of drug, nucleic acid molecule or a polypeptide; antibody RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) 2008-01-10 US claimed
EP-1781310-A2 ARTICLES OF PEPTIDE NANOSTRUCTURES AND METHOD OF FORMING THE SAME Ramot at Tel Aviv University Ltd. (IL) 2007-05-09 EP claimed
WO-2007043048-A2 SELF-ASSEMBLED FMOC-FF HYDROGELS RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) 2007-04-19 WO claimed
US-20060079455-A1 Peptide nanostructures encapsulating a foreign material and method of manufacturing same RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) 2006-04-13 US claimed
US-20060079454-A1 Peptide nanostructures and methods of generating and using the same RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) 2006-04-13 US claimed
WO-2006027780-A2 PEPTIDE NANOSTRUCTURES CONTAINING END-CAPPING MODIFIED PEPTIDES AND METHODS OF GENERATING AND USING THE SAME RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) 2006-03-16 WO claimed
WO-2006013552-A2 ARTICLES OF PEPTIDE NANOSTRUCTURES AND METHOD OF FORMING THE SAME RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) 2006-02-09 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210030918-A1 COATING OF FIBERS WITH DIPEPTIDE NANOSTRUCTURES USING ULTRASONIC CAVITATION VIP, NPPA, IAPP CA12 900/4885CA14 414/4885CA2 2360/4885
US-20080009434-A1 at least one aromatic amino acid (phenylalanine); hollow and fibrillar peptide; macroscopic and microscopic articles; self-assembled; 9-fluorenylmethyloxycarbonyl (Fmoc) and benzyloxycarbonyl (Cbz); slow release of drug, nucleic acid molecule or a polypeptide; antibody DNPEP, LNPEP, ANPEP CA12 402/4885CA14 294/4885CA2 641/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.